The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Yusupov F.A.

Osh State University, Osh, Kyrgyz Republic

Abdykadyrov M.Sh.

Osh State University, Osh, Kyrgyz Republic

Relationship between kidney-related brain dysfunction and neuropathological changes in Parkinson’s disease

Authors:

Yusupov F.A., Abdykadyrov M.Sh.

More about the authors

Read: 254 times


To cite this article:

Yusupov FA, Abdykadyrov MSh. Relationship between kidney-related brain dysfunction and neuropathological changes in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(3):30‑37. (In Russ.)
https://doi.org/10.17116/jnevro202612603130

Recommended articles:
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14

References:

  1. Yusupov FA, Ydyrysov IT, Abdykadyrov MSh, et al. Age and gender aspects of parkinson’s disease. Klinicheskaya medicina. 2025;103(1):13-22. (In Russ.). https://doi.org/10.30629/0023-2149-2025-103-1-13-22
  2. Prajjwal P, Flores Sanga HS, Acharya K, et al. Parkinson’s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment. Ann Med Surg (Lond). 2023;85(10):4887-4902. https://doi.org/10.1097/MS9.0000000000001142
  3. Katunina EA, Zalyalova ZA, Pokhabov DV, et al. Art and creativity in Parkinson’s disease: the mysterious effects of dopamine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(4):13-20. (In Russ.). https://doi.org/10.17116/jnevro202512504113
  4. Pilipovich AA, Vorob’eva OV, Makarov SA. Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(4):59-67. (In Russ.). https://doi.org/10.17116/jnevro202512504159
  5. Kulcsarova K, Skorvanek M, Postuma RB, Berg D. Defining Parkinson’s Disease: Past and Future. J Parkinsons Dis. 2024;14(s2):S257-S271. https://doi.org/10.3233/JPD-230411
  6. Chang K-H, Chen C-M. The Role of Oxidative Stress in Parkinson’s Disease. Antioxidants. 2020;9(7):597.  https://doi.org/10.3390/antiox9070597
  7. Murkamilov IT, Sabirov IS, Murkamilova ZA, et al. Prevalence of risk factors for cerebrovascular diseases in patients with chronic kidney disease and renal failure. Klinicheskaya nefrologiya. 2022;14(3):39-51. (In Russ.). https://doi.org/10.18565/nephrology.2022.3.39-51.
  8. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294-1304. https://doi.org/10.1001/jama.2019.14745
  9. Murkamilov IT, Aytbaev KA, Fomin VV, et al. Kidney damage in hypertensive disease. Klinicheskaya medicina. 2023;101(11):569-576. (In Russ.). https://doi.org/10.30629/0023-2149-2023-101-11-569-576
  10. Kwon MJ, Kim JK, Kim JH, et al. Exploring the Link between Chronic Kidney Disease and Parkinson’s Disease: Insights from a Longitudinal Study Using a National Health Screening Cohort. Nutrients. 2023;15(14):3205. https://doi.org/10.3390/nu15143205
  11. Murkamilov IT, Aitbaev KA, Yusuupov FA, et al. Chronic kidney failure and ischemic heart disease: Medical and social aspects. Byulleten’ nauki i praktiki. 2025;11(6):314-333. (In Russ.). https://doi.org/10.33619/2414-2948/115/40
  12. Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018;243(3):213-221.  https://doi.org/10.1177/1535370217750088
  13. Arya R, Haque AKMA, Shakya H, et al. Parkinson’s Disease: Biomarkers for Diagnosis and Disease Progression. International Journal of Molecular Sciences. 2024;25(22):12379. https://doi.org/10.3390/ijms252212379
  14. Wang J, Hoekstra JG, Zuo C, et al. Biomarkers of Parkinson’s disease: current status and future perspectives. Drug Discov Today. 2013;18(3-4):155-162.  https://doi.org/10.1016/j.drudis.2012.09.001
  15. Halabi S, Owzar K. The importance of identifying and validating prognostic factors in oncology. Semin Oncol. 2010;37(2):e9-e18.  https://doi.org/10.1053/j.seminoncol.2010.04.001
  16. Hu WD, Chen J, Mao CJ, et al. Elevated Cystatin C Levels Are Associated with Cognitive Impairment and Progression of Parkinson Disease. Cogn Behav Neurol. 2016;29(3):144-149.  https://doi.org/10.1097/WNN.0000000000000100
  17. Wang YN, Ma SX, Chen YY, et al. Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clin Chim Acta. 2019;499:54-63.  https://doi.org/10.1016/j.cca.2019.08.030
  18. Liabeuf S, Pepin M, Franssen CFM, et al. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? Nephrol Dial Transplant. 2022 ;37(8):1589. https://doi.org/10.1093/ndt/gfac015
  19. Yuan X, Nie S, Yang Y, et al. Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease. Nat Neurosci. 2025;28(3):577-588.  https://doi.org/10.1038/s41593-024-01866-2
  20. Assem M, Lando M, Grissi M, et al. The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders. Toxins (Basel). 2018;10(7):303.  https://doi.org/10.3390/toxins10070303
  21. Arena G, Sharma K, Agyeah G, et al. Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop. Curr Neurol Neurosci Rep. 2022;22(8):427-440.  https://doi.org/10.1007/s11910-022-01207-5
  22. Chagas YW, Vaz de Castro PAS, Simões-E-Silva AC. Neuroinflammation in kidney disease and dialysis. Behav Brain Res. 2025;483:115465. https://doi.org/10.1016/j.bbr.2025.115465
  23. Trevisan L, Gaudio A, Monfrini E, et al. Genetics in Parkinson’s disease, state-of-the-art and future perspectives. Br Med Bull. 2024;149(1):60-71.  https://doi.org/10.1093/bmb/ldad035
  24. Luo Y, Hoffer A, Hoffer B, et al. Mitochondria: A Therapeutic Target for Parkinson’s Disease? International Journal of Molecular Sciences. 2015;16(9):20704-20730. https://doi.org/10.3390/ijms160920704
  25. Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399. https://doi.org/10.1101/cshperspect.a009399
  26. Lema Tomé CM, Tyson T, Rey NL, et al. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease — is there a link? Mol Neurobiol. 2013;47(2):561-574.  https://doi.org/10.1007/s12035-012-8267-8
  27. Yuan X, Nie S, Yang Y, et al. Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease. Nat Neurosci. 2025;28(3):577-588.  https://doi.org/10.1038/s41593-024-01866-2
  28. Murkamilov IT, Aitbaev KA, Murkamilova ZA, et al. Modern biomarkers of renal dysfunction in the elderly and senile age: Clinical and prognostic significance. Uspekhi gerontologii. 2022;35(6):862-868. (In Russ.). https://doi.org/10.34922/AE.2022.35.6.007
  29. Qu Y, Qin QX, Wang DL, et al. Estimated glomerular filtration rate is a biomarker of cognitive impairment in Parkinson’s disease. Front Aging Neurosci. 2023;15:1130833. https://doi.org/10.3389/fnagi.2023.1130833
  30. Murkamilova ZA, Sabirov IS, Fomin VV, et al. Cystatin C and vascular stiffness as markers of nephrovascular and cerebrovascular diseases in elderly and senile individuals. Vestnik Kyrgyzsko-Rossijskogo Slavyanskogo universiteta. 2020;20(5):34-44. EDN NGQQDE. (In Russ.).
  31. Xiong KP, Dai YP, Chen J, et al. Increased Serum Cystatin C in Early Parkinson’s Disease with Objective Sleep Disturbances. Chin Med J (Engl). 2018;131(8):907-911.  https://doi.org/10.4103/0366-6999.229902
  32. Hu WD, Chen J, Mao CJ, et al. Elevated Cystatin C Levels Are Associated with Cognitive Impairment and Progression of Parkinson Disease. Cogn Behav Neurol. 2016;29(3):144-149.  https://doi.org/10.1097/WNN.0000000000000100
  33. Seifar F, Dinasarapu AR, Jinnah HA. Uric Acid in Parkinson′s Disease: What Is the Connection? Movement Disorders. 2022;37(11):2173-2183. Portico. https://doi.org/10.1002/mds.29209
  34. Yusupov FA, Yuldashev AA, Abdykadyrov MSh, et al. Effect of uric acid on the progression of Parkinson’s disease: Myth or reality? S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7):7-14. (In Russ.). https://doi.org/10.17116/jnevro20251250717
  35. Ma L-Y, Tian Y, Pan C-R, et al. Motor Progression in Early-Stage Parkinson’s Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers. Aging Neurosci. 2021;12:627199. https://doi.org/10.3389/fnagi.2020.627199
  36. Zafar S, Yaddanapudi SS. Parkinson Disease. 2023.
  37. Qu Y, Qin Q-X, Wang D-L, et al. Estimated glomerular filtration rate is a biomarker of cognitive impairment in Parkinson’s disease. Aging Neurosci. 2023;15:1130833. https://doi.org/10.3389/fnagi.2023.1130833

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.